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One of the major obstacles of immunosuppressive therapy
(IST) in children with severe aplastic anemia (SAA) comes from
the often months-long unpredictability of bone-marrow (BM)
recovery. In this prospective study in children with newly
diagnosed very severe AA (n¼10), who were enrolled in the
therapy study SAA-BFM 94, we found a dramatically reduced
diversity of both CD4þ and CD8þ BM cells, as scored by
comprehensive V-beta chain T-cell receptor (TCR) analysis.
Strongly skewed TCR V-beta pattern was highly predictive for
good or at least partial treatment response (n¼6, CD8þ
complexity scoring median 35.5, range 24–73). In contrast, IST
in patients with rather moderate reduction of TCR V-beta
diversity (n¼4, CD8þ complexity scoring median 109.5, range
82–124) always failed (P¼0.0095). If conﬁrmed in a larger series
of patients, TCR V-beta repertoire in BM may help to assign
children with SAA up-front either to IST or to allogeneic stem-
cell transplantation.
Blood Cancer Journal (2011) 1, e8; doi:10.1038/bcj.2011.6;
published online 4 March 2011
Keywords: aplastic anemia; T-cell receptor V-beta chain repertoire;
children
Introduction
The assumption that severe aplastic anemia (SAA) clinically
presenting with severe pancytopenia and extreme bone-marrow
(BM) hypocellularity can be treated successfully by profound
immunosuppression dates back to 1970, when a striking
observation was made: Patients who were ‘myeloablatively’
conditioned by high-dose chemotherapy for intended allogeneic
BM transplantation but inadvertently rejected the graft and
reconstituted with their own marrow subsequently remained
free of disease.
1
Today, there is overwhelming evidence that a pathological
autoimmune response mediated by oligoclonally expanded
populations of autologous T cells causes a signiﬁcant decrease
in the number of hematopoietic stem and progenitor cells.
2–4
Fortunately, anti-T-cell treatment with cyclosporine A, pre-
dnisolone and antithymocyte globulin leads to hematological
recovery in the majority of patients.
Nevertheless, 20–30% of SAA patients do not respond to
these drugs, which becomes apparent after a long latency of
approximately 6 months following onset of therapy. The long
duration before recovery of marrow function is closely related to
the risk of severe complications and thus worsens the overall
outcome in this group of patients. This latency period also
prevents early stratiﬁcation for BM transplantation in those
patients without matched sibling donor and who will subse-
quently fail.
5 Thus, early clinical decision-making pro- or
contra-allogeneic stem-cell transplantation in patients with
SAA remains a challenge.
We previously showed that children with very severe AA
(vSAA; all nucleated cells (ANC) o0.2 10
9/l at diagnosis)
show a higher rate of complete response to immunosuppressive
therapy (IST) and better survival than children with ‘only’ severe
AA (ANC 40.2 10
9/l at diagnosis).
6 Although counterintuitive
at ﬁrst view, a more severe form responds better to therapy.
However, this simple clinical approach does not help to
identify IST failures among the group of children with vSAA,
which is the most predominant subset. On the basis of our
clinical observation, we hypothesized that the strength of the
autoimmune attack is reﬂected in the degree of globally
restricted T-cell receptor (TCR) repertoire. BM and peripheral
blood (PB) CD4þ and CD8þ T cells were therefore selectively
analyzed by spectratyping (using the immunoscope technique)
at diagnosis, which gives insights into the overall T-cell diversity
by determining the TCR CDR3 length polymorphisms. For
control purposes, we included children with refractory cyto-
penia (RC, n¼8) and healthy age-matched control BM (n¼4).
Patients and methods
Patients and controls
Pediatric vSAA patients (n¼10) were diagnosed according to
the criteria of the German SAA 1994 study group
6 and Fanconi
anemia was excluded by chromosomal fragility test. For
comparison between vSAA and myelodysplastic syndrome, we
also assayed children with RC (n¼8) according to the EWOG
MDS-98 criteria.
7
Cytological evaluation and histology of BM biopsies were
centrally reviewed in all cases. Informed consent prior to
sampling was obtained and spectratyping was done prospec-
tively. All children were enrolled in the multicenter BFM-SAA
94 therapy study. Treatment consisted of antithymocyte globulin
(horse, 0.75ml/kg body weight (BW)) for 8 days, CsA (5mg/kg
BW, adjusted to blood levels), prednisolone (1–2mg/kg BW,
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After 6 months of therapy, vSAA patients were assigned either
to the group ‘IST responder’ (further subdivided into complete
responder (CR): ANC 41.5 10
9/l, hemoglobin according to
the age-adjusted cut-off, platelets 4150 10
9/l; and ‘partial
responder’ (PR): ANC 40.5 10
9/l, independent of red-cell
transfusions, platelets 420 10
9/l) or to the group ‘non-
responder’ (NR, neither CR nor PR).
The control group consisted of age-matched healthy children
donating BM for their siblings (n¼4).
Sample preparation and spectratype analysis
Mononuclear cells from BM and PB taken at diagnosis were
separated by Ficoll density centrifugation. CD4þ and CD8þ
lymphocytes were positively selected by using Dynabeads
(Dynal, Oslo, Norway). Total RNA of 100000 lymphocytes
was extracted and complementary DNA synthesis was per-
formed by standard procedures. For spectratyping, 26 TCR
V-beta-speciﬁc forward primers and a TCR C-beta reverse
primer were combined to amplify all V-beta TCR families
individually. Primer sequences are provided in Supplementary
Table 1. Subsequent run-off reactions with ﬂuorescence-labelled
J beta primers and analyses of resulting PCR products on a ABI
377 DNA sequencer (Applied Biosystems, Darmstadt, Germany)
were done exactly as described previously.
8
V-beta TCR complexity scoring
The complexity of single V-beta CDR3 was determined by
counting the number of distinct peaks and graded on a score of
0–8.
9 A score of 8 describes a normal CDR3 size variability of
8–10 peaks with a Gaussian distribution, a score of 1 was given
to proﬁles showing single peaks, 0 was given in case of absence
of peaks. The overall TCR complexity (complexity score) was
determined by summing up all 26 individual TCR V-beta family-
speciﬁc single scores (with a maximum of 26 8¼208).
Scoring was done blindly without any prior knowledge
regarding which group the patient belongs to. For a representa-
tive example, see Figure 1.
Statistics
The distributions of scores among patients were compared using
Mann–Whitney’s U-test. The distributions of scores within
patients (BM versus PB) were compared using two-sided
Wilcoxon’s test (paired samples).
Results
BM samples of 10 children with vSAA were examined at
diagnosis. In six of them (three CR/PR, three NR) cells from the
PB also could be analyzed. At ﬁrst, we compared the complexity
scores in BM and PB of CD4þ and CD8þ cells (Figure 2).
V-beta chain complexities of BM (CD4þ cells: median 86,
range: 10–166 and CD8þ cells: median 64, range 24–188)
were signiﬁcantly lower than those of PB (CD4þ cells: median
106, range 96–166; CD8þ cells: median 162, range 130–196;
CD4þ cells: P¼0.003; CD8þ cells: Po0.001).
A signiﬁcant skewness in vSAA patients was observed
compared with healthy controls in BM (healthy: CD4þ cells:
median 181, range 162–203; CD8þ cells: median 184, range
175–198; CD4þ cells: P¼0.004, CD8þ cells: P¼0.002) but
not in PB (healthy: CD4þ cells: median 184, range 180–202;
CD8þ cells: median 198, range 179–200; CD4þ cells:
P¼0.17, CD8þ cells: P¼0.062).
In contrast, analysis of the complexity score in the BM
between patients suffering from SAA and those suffering from RC
Figure 1 Illustrative example of selected TCR V-beta CDR3 spectratypes in a patient with partial response (PR)/complete response (CR) (left) and
in a patient with non-response (right). The number represents the speciﬁc V-beta chain family, followed by the complexity score in parentheses.
The inter-observer variability in spectratype complexity scoring was less than 5%, as determined by a blinded review of three individual cases by
three different investigators.
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CD4þ cells: median 118, range 30–175; CD8þ cells: median
92, range 12–150; CD4þ cells: P¼0.62, CD8þ cells: P¼0.57).
Next, we compared T-cell V-beta diversities of CD4þ and
CD8þ populations isolated from the BM of patients with CR/PR
(n¼6) or NR (n¼4). Notably, the grade of skewing in the BM of
SAA patients was highly associated with the subsequent
response to immunosuppressive treatment. NR had scoring
points from 82 up to 166 (CD4þ cells: median 138, range
87–166; CD8þ cells: median 109, range 82–124), much higher
than the CR/PR group (CD4þ cells: median 80, range 10–114;
CD8þ cells median 35.5, range 24–73; CD4þ cells:
P¼0.019, CD8þ cells: P¼0.0095; Figure 3).
Discussion
The extremely low amount of residual cells at diagnosis of vSAA
complicates comprehensive molecular testing in both adults and
children. Nevertheless, current research has revealed new
aspects in the pathophysiology of SAA: (a) telomere length
correlates with the rate of relapse, clonal evolution and overall
survival
10 and (b) increased Th17 cell number contributes to the
pathophysiology of SAA.
11 Nevertheless, there is still no valid
biomarker that really predicts the response to IST and could
therefore be used for justiﬁcation of early donor search in
patients who lack a matched sibling donor.
At ﬁrst, we asked whether the complexity score between
T-cells isolated from the BM differed from those isolated from PB.
V-beta chain complexities of BM CD4þ and CD8þ cells
were signiﬁcantly lower than those of PB (Figure 2, CD4+:
P¼0.003, CD8+: Pp0.001). Thus, skewing was evident in both
CD4þ and CD8þ BM cells but not in CD4þ and CD8þ cells
isolated from PB in comparison with healthy controls. These
results indicate that the autoimmune process with antigen-
induced T-cell proliferation occurs predominantly in the BM,
where the assumed target hematopoietic progenitor cells reside.
In practical terms, PB cannot be used instead of BM to perform
TCR V-beta complexity analysis. Skewed TCR repertoires were
previously observed in CD4þ and CD8þ cell fractions of
individual SAA patients in BM,
12 PB,
13 or by high-resolution
analysis.
14
There was no skewing and no difference between BM and PB
when CD4þ and CD8þ cells from healthy children (n¼4)
were tested. The overall complexity in the healthy children was
remarkably stable, with scores ranging from 162 to 202 (Figure 2,
Supplementary Table 2). We also did not observe a difference in
the BM TCR V-beta chain complexity between the vSAA and RC
Figure 2 Comparison of T-cell complexity scores in CD4þ and CD8þ T cells between peripheral blood (PB) and bone marrow (BM). Each
colored sign represents the overall score of a single patient. cont, healthy, age-matched controls; RC, refractory cytopenia; SAA, severe aplastic
anemia.
Figure 3 TCR V-beta chain diversities from bone-marrow lymphocytes according to the therapy response (response criteria as deﬁned in the
therapy study SAA-BFM 94). CR, complete remission; NR, non-responder; PR, partial remission.
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P¼0.62, CD8þ: P¼0.57). The fact that RC and vSAA patients
did not signiﬁcantly differ in their scoring points argues for akin
pathophysiology. Along this line, IST may lead to full BM
recovery in RC and SAA.
As expected, there was no difference between CR/PR and NR
when only PB was analyzed (Supplementary Table 2).
Altogether, when the CD8þ compartment is considered, a
cut-off complexity score of 130 separated both responders and
non-responders from healthy controls and a score of 80
distinguished the CR/PR group from the NR group without any
overlap between the patient groups. Besides the CD8þ cut-off
values of 130 and 80, respectively, there was no relation
between score, disease presentation and responsiveness. An
additional drawback of our study comes from the fact that the
current methodology of CDR3 polymorphism analysis is
extremely laborious and time-consuming. Analyses of all-
encompassing 26 TCR V-beta chain families with all 13 J-beta
segments in the CD4þ and CD8þ subsets require 676
individual PCR reactions in each individual patient. Thus, we
currently work on easier protocols based on 454-sequencing of
PCR products that were ampliﬁed with degenerative, wobbled
TCR V-beta primers. Once developed, such less-time-consum-
ing methodology to determine TCR complexity may have the
potential to become a tool for early treatment stratiﬁcation in
children with SAA, if conﬁrmed by other study groups.
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